Bacillus clausii Reduces Intestinal Damage from Chemotherapy in Mice
Author Information
Author(s): Francisco Ronaldo Farias Lima, Carlos Eduardo da Silva Monteiro, Samara Rodrigues Bonfim Damasceno, Patricia da Silva Pantoja, Álvaro Xavier Franco, Renan Oliveira Silva, Johnatan Alisson Oliveira Sousa, Tiago Santos Mendes, Marcos Aurélio Lima, Priscilla Fernanda Campos Justino, Marcellus Henrique Loiola Ponte de Souza, Pedro Marcos Gomes Soares, Luís M. T. Frija
Primary Institution: Federal University of Ceará
Hypothesis
Does Bacillus clausii mitigate the effects of 5-Fluorouracil-induced intestinal mucositis in mice?
Conclusion
Bacillus clausii may be a potential treatment for chemotherapy-induced intestinal mucositis by reducing inflammation and oxidative stress.
Supporting Evidence
- Bacillus clausii reduced weight loss in mice treated with 5-Fluorouracil.
- The probiotic improved histopathological scores in the ileum.
- Bacillus clausii decreased levels of inflammatory markers like IL-1β and TNF-α.
- The treatment restored gastrointestinal motility affected by 5-Fluorouracil.
- Bacillus clausii improved intestinal permeability in the study.
Takeaway
This study shows that a probiotic called Bacillus clausii can help protect mice from stomach problems caused by a cancer drug.
Methodology
Mice were treated with 5-Fluorouracil and Bacillus clausii, followed by evaluation of weight loss, histopathological changes, and various biochemical markers.
Limitations
The study was conducted only in mice, which may not fully represent human responses.
Participant Demographics
Male Swiss mice, 25-30 g.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website